Eli Lilly (NYSE: LLY) stock has had plenty of good trading sessions over the past year or so, but Monday's sure wasn't among ...

CEO David Ricks got a 10% raise in 2024, as a surge in demand for weigh-loss drugs has propelled the pharma giant into the ...

A new study found that fair prices for medications like Wegovy and Zepbound would be hundreds less per month than they are ...

We recently published a list of 12 Best Quality Stocks to Invest in Now. In this article, we are going to take a look at ...

Whales with a lot of money to spend have taken a noticeably bullish stance on Eli Lilly. Looking at options history for Eli ...

A study in people with obesity and diabetes again found CagriSema helps people lose weight, but not by enough to clearly ...

Roller-coaster healthcare stock Hims & Hers Health ( HIMS -1.34%), whose stock got devastated last week by worries that it ...

Wegovy and Zepbound — are cutting prices to make the medications more affordable for people without insurance.

To be a person in the year 2025 is to encounter, in one way or another, the marketing onslaught for compounded ...

Presiding over the upward trajectory of Eli Lilly over the last eight years is paying off nicely for CEO David Ricks. | ...

Compounded versions of popular drugs used for weight loss including Wegovy and Zepbound will soon no longer be available ...

"People come together, operators, with their supervisors at 6 a.m. every morning, and they talk about what issues they have and how they propose to solve it. Those get escalated through all levels of ...